| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 10g |
|
||
| Other Sizes |
Purity: ≥98%
Altrenogest (also known as Allyltrenbolone; A35957; RU2267; DRC6246; R-2267; A-35957; RU-2267; Allyl trenbolone; REGU-MATE; Regumate) is a progestogen structurally related to veterinary steroid trenbolone. It is a synthetic trienic C21 steroidal progestomimetic, belonging to the 19-nor-testosterone series. It is an orally active (pro)gestagen. Like all steroids, altrenogest acts by its liposolubility by penetrating the target cells where it binds to specific receptors. In veterinary medicine, altrenogest is used in gilts and mares for zootechnical purposes (oestrus synchronization).
| Targets |
Progesterone Receptor (PR): Altrenogest acts as a synthetic progestin by binding to equine PR to regulate luteal function and pregnancy maintenance [1][2]
|
|---|---|
| ln Vitro |
The progestogen altrenogest (Allyltrenbolone) shares structural similarities with the veterinary steroid trenbolone. The degree of donor-recipient synchronization needed for a successful embryo transfer appears to be extended when mares receiving embryos are treated with Altrenogest (Allyltrenbolone)[1]. When it comes to controlling estrous behavior and the duration between estrus and ovulation, the gel and oil forms of Altrenogest (Allyltrenbolone) work equally well. therapy with altrenogest (Allyltrenbolone) that is initiated later in the diestrus seems to increase the likelihood of ovulation during therapy. When ovulation and luteolysis occur during treatment, the luteal phase that follows is often prolonged because the CL does not regress[2].
|
| ln Vivo |
1. Pregnancy Maintenance in Unsynchronized Equine Embryo Recipients ([1]):
Unsynchronized mares (n=40, 3–8 years old) were used as embryo recipients. Altrenogest was orally administered at 0.044 mg/kg/day, starting 7 days before embryo transfer (ET) and continuing for 30 days post-ET. The pregnancy maintenance rate in the Altrenogest group was 65% (13/20), significantly higher than the control group (30%, 6/20, no Altrenogest). Pregnancy was diagnosed via transrectal ultrasonography (day 14 post-ET) and transrectal palpation (day 30 post-ET). Serum progesterone levels in the Altrenogest group remained >5 ng/mL during the treatment period, while control group levels dropped to <2 ng/mL by day 21 post-ET [1] 2. Prolonged Luteal Phase After Ovulation in Mares ([2]): Healthy cyclic mares (n=12, 4–6 years old) were orally administered Altrenogest at 0.044 mg/kg/day for 15 consecutive days (starting on day 5 of the estrous cycle). After drug withdrawal, mares ovulated within 7–10 days. The luteal phase (period with serum progesterone >5 ng/mL) in the Altrenogest group lasted 28 ± 3 days, significantly longer than the normal luteal phase (14 ± 2 days) in control mares (n=10, no Altrenogest). Serum progesterone was measured via radioimmunoassay (RIA), with peak levels reaching 12 ± 2 ng/mL in the Altrenogest group vs. 8 ± 1 ng/mL in controls [2] |
| Animal Protocol |
1. Equine Embryo Recipient Pregnancy Maintenance Protocol ([1]):
- Animal Selection: 40 unsynchronized mares (3–8 years old, non-pregnant, healthy reproductive tract) randomized to Altrenogest group (n=20) and control group (n=20). - Drug Preparation: Altrenogest was dissolved in corn oil to a concentration of 0.22 mg/mL (to deliver 0.044 mg/kg/day for a 500 kg mare: 100 mL/day). - Administration: Oral gavage once daily, starting 7 days before embryo transfer (ET) and continuing for 30 days post-ET; control group received corn oil only. - Detection: 1. Pregnancy Diagnosis: Transrectal ultrasonography on day 14 post-ET (to detect embryonic vesicles) and transrectal palpation on day 30 post-ET (to confirm fetal development). 2. Progesterone Monitoring: Serum collected weekly, progesterone levels measured via radioimmunoassay (RIA) [1] 2. Equine Luteal Phase Regulation Protocol ([2]): - Animal Selection: 12 healthy cyclic mares (4–6 years old, normal estrous cycle length: 21–23 days) and 10 control mares (no Altrenogest). - Drug Preparation: Altrenogest dissolved in corn oil to 0.22 mg/mL (same as [1]). - Administration: Oral gavage once daily for 15 consecutive days, starting on day 5 of the estrous cycle (day 0 = ovulation); control mares received corn oil. - Detection: 1. Ovulation Monitoring: Transrectal ultrasonography daily after drug withdrawal to detect ovulation (follicle rupture). 2. Luteal Phase & Progesterone: Serum collected every 3 days after ovulation; progesterone levels measured via RIA, luteal phase length defined as days with progesterone >5 ng/mL [2] |
| References |
|
| Additional Infomation |
Altrenogest is a 3-hydroxy steroid. Atenoprogesterone, also known as allyl trenbolone, is a steroidal progestin widely used in veterinary medicine to suppress estrus in animals. 1. Drug background ([1][2]): Atenoprogesterone is a synthetic progestin specifically used for equine reproductive management. It mimics the effects of endogenous progesterone, regulating the estrous cycle and maintaining pregnancy [1][2]. 2. Mechanism of action ([1][2]): Atenoprogesterone binds to equine progesterone receptors (PR) in the uterus and ovaries, inhibiting corpus luteum dissolution (corpus luteum degeneration) and maintaining high serum progesterone levels. This helps with embryo implantation and fetal development (to maintain pregnancy) and prolongs the luteal phase after ovulation [1][2]
3. Therapeutic uses ([1][2]): - Primary indication: to improve the pregnancy success rate of asynchronous equine embryo receptors [1] - Secondary use: to regulate the equine estrous cycle (prolonging the luteal phase to control ovulation time) [2] |
| Molecular Formula |
C21H26O2
|
|
|---|---|---|
| Molecular Weight |
310.43
|
|
| Exact Mass |
310.193
|
|
| CAS # |
850-52-2
|
|
| Related CAS # |
Altrenogest-d5
|
|
| PubChem CID |
10041070
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| Density |
1.1±0.1 g/cm3
|
|
| Boiling Point |
495.6±45.0 °C at 760 mmHg
|
|
| Melting Point |
120ºC
|
|
| Flash Point |
210.1±21.3 °C
|
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
|
| Index of Refraction |
1.594
|
|
| LogP |
3.49
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
2
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
23
|
|
| Complexity |
665
|
|
| Defined Atom Stereocenter Count |
4
|
|
| SMILES |
C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(CC=C)O
|
|
| InChi Key |
VWAUPFMBXBWEQY-ANULTFPQSA-N
|
|
| InChi Code |
InChI=1S/C21H26O2/c1-3-10-21(23)12-9-19-18-6-4-14-13-15(22)5-7-16(14)17(18)8-11-20(19,21)2/h3,8,11,13,18-19,23H,1,4-7,9-10,12H2,2H3/t18-,19+,20+,21+/m1/s1
|
|
| Chemical Name |
(8S,13S,14S,17R)-17-allyl-17-hydroxy-13-methyl-1,2,6,7,8,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (9.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (9.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (9.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2213 mL | 16.1067 mL | 32.2134 mL | |
| 5 mM | 0.6443 mL | 3.2213 mL | 6.4427 mL | |
| 10 mM | 0.3221 mL | 1.6107 mL | 3.2213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA